 |
218 Diseases |  |
9 Trials |
|
9 Trials |  |
244 News |  |
| «12345» |
- | Kepivance (palifermin) / SOBI, Amgen
Trial completion: Pharmacokinetic Study of Palifermin in Subjects Receiving Radiation Therapy and Chemotherapy Followed by Blood Stem Cell Support (clinicaltrials.gov) - Feb 27, 2016
P1, N=25, Completed, Sponsor: Swedish Orphan Biovitrum
Recruiting --> Completed
- Campath (alemtuzumab) / Sanofi, Kepivance (palifermin) / SOBI, Amgen
New P2 trial: A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors (clinicaltrials.gov) - Jan 15, 2016
P2, N=30, Recruiting, Sponsor: Montefiore Medical Center
- Kepivance (palifermin) / SOBI, Amgen
Trial primary completion date, Metastases: Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - Dec 17, 2015
P2, N=52, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting --> Completed Trial primary completion date: Feb 2016 --> Feb 2017
- | Zolinza (vorinostat) / Merck (MSD)
New P1/2 trial: Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype (clinicaltrials.gov) - Oct 28, 2015
P1/2, N=30, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- Zolinza (vorinostat) / Merck (MSD)
Trial completion, Trial primary completion date: Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies (clinicaltrials.gov) - Sep 18, 2015
P1, N=78, Completed, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Feb 2016 --> Feb 2017 Active, not recruiting --> Completed | Trial primary completion date: Aug 2016 --> Sep 2015
- melphalan / Generic mfg., busulfan / Generic mfg., gemcitabine / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma (clinicaltrials.gov) - Aug 11, 2015
P2, N=5, Terminated, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Completed | Trial primary completion date: Aug 2016 --> Sep 2015 N=24 --> 5 | Active, not recruiting --> Terminated | Trial primary completion date: Feb 2015 --> Jun 2015; Slow accrual and futility
- Kepivance (palifermin) / SOBI, Amgen
Enrollment open: Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (clinicaltrials.gov) - May 5, 2015
P1/2, N=50, Recruiting, Sponsor: National Cancer Institute (NCI)
N=24 --> 5 | Active, not recruiting --> Terminated | Trial primary completion date: Feb 2015 --> Jun 2015; Slow accrual and futility Not yet recruiting --> Recruiting
- melphalan / Generic mfg., busulfan / Generic mfg., gemcitabine / Generic mfg.
Enrollment closed, Trial primary completion date: High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease (clinicaltrials.gov) - Apr 13, 2015
P2, N=80, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2016 --> Aug 2017
- ||||||| Kepivance (palifermin) / SOBI, Amgen
Trial completion: A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma (clinicaltrials.gov) - Mar 10, 2015
P3, N=281, Completed, Sponsor: Swedish Orphan Biovitrum
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2016 --> Aug 2017 Active, not recruiting --> Completed
- Kepivance (palifermin) / SOBI, Amgen
New P1/2 trial: Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (clinicaltrials.gov) - Feb 5, 2015
P1/2, N=50, Recruiting, Sponsor: National Cancer Institute (NCI)
- |||| Kepivance (palifermin) / SOBI, Amgen
Trial completion, Metastases: Study to Evaluate Palifermin in the Reduction of Dysphagia in Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Jan 5, 2015
P2, N=100, Completed, Sponsor: Swedish Orphan Biovitrum
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Kepivance (palifermin) / SOBI, Amgen
Trial primary completion date, Metastases: Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - Dec 17, 2014
P2, N=52, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Trial primary completion date: Feb 2014 --> Feb 2016
- |||||||||| Kepivance (palifermin) / SOBI, Amgen
New P3 trial, HEOR: Palifermin for Patients Receiving Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Dec 10, 2014
P3, N=88, Not yet recruiting, Sponsor: The Catholic University of Korea
- melphalan / Generic mfg., busulfan / Generic mfg., gemcitabine / Generic mfg.
Trial primary completion date: High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease (clinicaltrials.gov) - Nov 14, 2014
P2, N=80, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Feb 2014 --> Feb 2016 Trial primary completion date: Aug 2015 --> Aug 2016
- Zolinza (vorinostat) / Merck (MSD)
Trial primary completion date: Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies (clinicaltrials.gov) - Nov 7, 2014
P1, N=80, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Aug 2015 --> Aug 2016 Trial primary completion date: Aug 2015 --> Aug 2016
- Kepivance (palifermin) / SOBI, Amgen
Phase classification: Palifermin DDI (Drug Drug Interaction) (clinicaltrials.gov) - Nov 6, 2014
P1, N=45, Completed, Sponsor: Swedish Orphan Biovitrum
Trial primary completion date: Aug 2015 --> Aug 2016 Phase classification: P4 --> P1
- |||| Kepivance (palifermin) / SOBI, Amgen
Trial completion, Trial initiation date: Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation (clinicaltrials.gov) - Sep 15, 2014
P2, N=155, Completed, Sponsor: Swedish Orphan Biovitrum
Phase classification: P4 --> P1 Active, not recruiting --> Completed | Initiation date: Aug 2005 --> Dec 2005
- melphalan / Generic mfg., busulfan / Generic mfg., gemcitabine / Generic mfg.
Enrollment closed: CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma (clinicaltrials.gov) - Jul 25, 2014
P2, N=24, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Completed | Initiation date: Aug 2005 --> Dec 2005 Recruiting --> Active, not recruiting
- ||||||| Kepivance (palifermin) / SOBI, Amgen
Trial completion, Metastases: A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Stage 2B or 3 Locally Advanced, Colon Cancer (clinicaltrials.gov) - Jul 15, 2014
P2/3, N=100, Completed, Sponsor: Amgen
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Zolinza (vorinostat) / Merck (MSD)
Clinical: Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma (clinicaltrials.gov) - Jul 12, 2014
P2, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed N=75 --> 0 | Not yet recruiting --> Withdrawn
- ||| Kepivance (palifermin) / SOBI, Amgen, Firmagon (degarelix) / Astellas, Ferring
Enrollment change: Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Jul 2, 2014
P2, N=120, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
N=75 --> 0 | Not yet recruiting --> Withdrawn N=180 --> 120
- melphalan / Generic mfg., busulfan / Generic mfg., gemcitabine / Generic mfg.
Enrollment closed: High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma (clinicaltrials.gov) - Apr 29, 2014
P2, N=75, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
N=180 --> 120 Recruiting --> Active, not recruiting
- Kepivance (palifermin) / SOBI, Amgen
Trial termination, Surgery, Metastases: Palifermin in Lessening Oral Mucositis in Patients Undergoing Radiation Therapy and Chemotherapy for Locally Advanced Head and Neck Cancer (clinicaltrials.gov) - Apr 15, 2014
P3, N=21, Terminated, Sponsor: Radiation Therapy Oncology Group
Recruiting --> Active, not recruiting Completed --> Terminated; Due to positive preliminary results from other palifermin studies.
- Kepivance (palifermin) / SOBI, Amgen, peripheral blood stem cell transplantation / National Cancer Institute
Trial completion: Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma (clinicaltrials.gov) - Apr 13, 2014
P1, N=38, Completed, Sponsor: Barbara Ann Karmanos Cancer Institute
Completed --> Terminated; Due to positive preliminary results from other palifermin studies. Active, not recruiting --> Completed
- | Zolinza (vorinostat) / Merck (MSD)
Clinical: Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma (clinicaltrials.gov) - Apr 10, 2014
P2, N=75, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- | Kepivance (palifermin) / SOBI, Amgen, Neupogen (filgrastim) / Kyowa Kirin, Amgen, peripheral blood stem cell transplantation / National Cancer Institute
Trial completion: Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer (clinicaltrials.gov) - Feb 19, 2014
P2, N=111, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Kepivance (palifermin) / SOBI, Amgen
Trial completion: Melphalan & Palifermin Followed by Peripheral Blood Stem Cell Transplant in Treating Pts w/Stage II-III Multiple Myeloma (clinicaltrials.gov) - Jan 19, 2014
P1, N=38, Completed, Sponsor: Barbara Ann Karmanos Cancer Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Kepivance (palifermin) / SOBI, Amgen
New P1/2 trial: Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis (clinicaltrials.gov) - Jan 12, 2014
P1/2, N=5, Recruiting, Sponsor: Brett King
- Kepivance (palifermin) / SOBI, Amgen
Enrollment open: Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis (clinicaltrials.gov) - Jan 12, 2014
P1/2, N=5, Recruiting, Sponsor: Brett King
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Zolinza (vorinostat) / Merck (MSD)
Enrollment closed: Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies (clinicaltrials.gov) - Jan 2, 2014
P1, N=80, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Kepivance (palifermin) / SOBI, Amgen
Enrollment closed, Metastases: Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - Dec 10, 2013
P2, N=52, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- melphalan / Generic mfg., busulfan / Generic mfg., gemcitabine / Generic mfg.
Enrollment change: High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma (clinicaltrials.gov) - Aug 22, 2013
P2, N=75, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting N=59 --> 75
- melphalan / Generic mfg., busulfan / Generic mfg., gemcitabine / Generic mfg.
Enrollment open: High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma (clinicaltrials.gov) - Aug 22, 2013
P2, N=75, Recruiting, Sponsor: M.D. Anderson Cancer Center
N=59 --> 75 Active, not recruiting --> Recruiting
- Zolinza (vorinostat) / Merck (MSD)
Enrollment change: Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies (clinicaltrials.gov) - Aug 20, 2013
P1, N=80, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Recruiting N=60 --> 80
- Kepivance (palifermin) / SOBI, Amgen
Enrollment change, Surgery, Metastases: Palifermin in Lessening Oral Mucositis in Patients Undergoing Radiation Therapy and Chemotherapy for Locally Advanced Head and Neck Cancer (clinicaltrials.gov) - Jun 25, 2013
P3, N=21, Completed, Sponsor: Radiation Therapy Oncology Group
N=60 --> 80 N=298 --> 21
- Kepivance (palifermin) / SOBI, Amgen
Enrollment change: Palifermin in Preventing Oral Mucositis Caused by Chemotherapy and/or Radiation Therapy in Young Patients Undergoing Stem Cell Transplant (clinicaltrials.gov) - May 29, 2013
P2, N=0, Withdrawn, Sponsor: Children's Oncology Group
N=298 --> 21 N=200 --> 0
- melphalan / Generic mfg., busulfan / Generic mfg., gemcitabine / Generic mfg.
Enrollment open: CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma (clinicaltrials.gov) - Feb 25, 2013
P2, N=24, Recruiting, Sponsor: Dana-Farber Cancer Institute
N=200 --> 0 Not yet recruiting --> Recruiting
- ||||| Kepivance (palifermin) / SOBI, Amgen, Firmagon (degarelix) / Astellas, Ferring
New P2 trial: Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Dec 9, 2012
P2, N=180, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
- melphalan / Generic mfg., busulfan / Generic mfg., gemcitabine / Generic mfg.
New P2 trial: CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma (clinicaltrials.gov) - Dec 6, 2012
P2, N=24, Recruiting, Sponsor: Dana-Farber Cancer Institute
- Kepivance (palifermin) / SOBI, Amgen
Trial completion, IO biomarker: Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer (clinicaltrials.gov) - Dec 4, 2012
P=N/A, N=6, Completed, Sponsor: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Lemtrada (alemtuzumab) / Sanofi
New P1/2 trial: CAM-THY: Keratinocyte Growth Factor to Prevent Autoimmunity After Alemtuzumab Treatment of Multiple Sclerosis (clinicaltrials.gov) - Oct 22, 2012
P1/2, N=86, Recruiting, Sponsor: Cambridge University Hospitals NHS Foundation Trust
- melphalan / Generic mfg., busulfan / Generic mfg., gemcitabine / Generic mfg.
Trial completion, Metastases: Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies (clinicaltrials.gov) - Sep 23, 2012
P1/2, N=145, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Kepivance (palifermin) / SOBI, Amgen
New P1 trial: Melphalan & Palifermin Followed by Peripheral Blood Stem Cell Transplant in Treating Pts w/Stage II-III Multiple Myeloma (clinicaltrials.gov) - Jul 30, 2012
P1, N=38, Completed, Sponsor: Barbara Ann Karmanos Cancer Institute
- || Kepivance (palifermin) / SOBI, Amgen
Trial completion: Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE) (clinicaltrials.gov) - Jul 12, 2012
P3, N=47, Completed, Sponsor: Swedish Orphan Biovitrum
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Kepivance (palifermin) / SOBI, Amgen
Trial initiation date, Metastases: Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer (clinicaltrials.gov) - Jul 11, 2012
P3, N=188, Active, not recruiting, Sponsor: Swedish Orphan Biovitrum
Active, not recruiting --> Completed Initiation date: Jan 2005 --> Aug 2005
- Kepivance (palifermin) / SOBI, Amgen, MB-207 / Fortress
Enrollment open: Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID) (clinicaltrials.gov) - May 25, 2012
P1/2, N=20, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases, St. Jude Children's Research Hospital
Initiation date: Jan 2005 --> Aug 2005 Suspended --> Recruiting
- Kepivance (palifermin) / SOBI, Amgen
Trial withdrawal: KGF Haplo Allo: Palifermin After Haploidentical PBSCT (clinicaltrials.gov) - May 8, 2012
P2, N=0, Withdrawn, Sponsor: European Group for Blood and Marrow Transplantation
Suspended --> Recruiting Not yet recruiting --> Withdrawn
- Kepivance (palifermin) / SOBI, Amgen
Enrollment change: KGF Haplo Allo: Palifermin After Haploidentical PBSCT (clinicaltrials.gov) - May 8, 2012
P2, N=0, Withdrawn, Sponsor: European Group for Blood and Marrow Transplantation
Not yet recruiting --> Withdrawn N=100 --> 0
- Kepivance (palifermin) / SOBI, Amgen
Trial completion: Dose Escalation Study Of Palifermin in Pediatric Research Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Mar 21, 2012
P1, N=19, Completed, Sponsor: St. Jude Children's Research Hospital
N=100 --> 0 Active, not recruiting --> Completed
- Kepivance (palifermin) / SOBI, Amgen, peripheral blood stem cell transplantation / National Cancer Institute
Enrollment change: Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma (clinicaltrials.gov) - Mar 7, 2012
P1, N=38, Completed, Sponsor: Barbara Ann Karmanos Cancer Institute
Active, not recruiting --> Completed N=30 --> 38